The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-15. Anything still debated is marked as such rather than presented as settled.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical lyophilized form |
| Solubility | Freely soluble in water | Also dissolves in common polar solvents |
| Storage temperature | Minus 20 degrees Celsius or lower | Applies to dry powder, desiccated and dark |
| Typical analytical methods | Reversed-phase HPLC and mass spectrometry | Used together for purity and identity |
| Primary degradation route | Hydrolysis and aggregation | No cysteine present, so disulfide formation is unlikely |
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
The great chain of being (from Latin scala naturae 'ladder of being') is a hierarchical structure of all matter and life, thought by the medieval Islamic world and medieval Christianity to have been decreed by God. The chain begins with God and descends through angels, humans, animals and plants to minerals. The great chain of being is a concept derived from Plato, Aristotle (in his Historia Animalium), Plotinus and Proclus. Further developed during the Middle Ages, it reached full expression in early modern Neoplatonism.
=== Refugees === On January 20, 2025, Trump signed the executive order named "Securing Our Borders". This order suspends the Uniting for Ukraine parole program, and no new applications from Ukrainian refugees with relatives in the United States are being accepted. On May 12, 59 white South African refugees arrived from South Africa. The Trump administration has been criticized for fast-tracking their applications while pausing other refugee programs. The Trump administration slowed the entry of Afghan refugees into the U.S., including persons who had fought on the U.S. side against the Taliban. A leader of an American veterans group said, "these pilots risked everything for America. Their lives are now on the line because of our failure to follow through on our promises." On May 12, Department of Homeland Security Secretary Noem announced that TPS, or temporary protected status, for Afghan refugees would be ended in 60 days, which is the shortest time period permitted by United States law. This decision cited improved conditions in Afghanistan. The Hill reports that the UN high commissioner for refugees has stated that the situation in Afghanistan has not improved, with a report stating "The large-scale returns are putting even greater pressure on already stretched humanitarian resources." On the other hand, Secretary Noem has pointed to an increase in tourists from China and a drop in the number of Afghans needing assistance from 29 million to 24 million.
In 2001, 35 patients filed a class-action suit alleging they had had withdrawal symptoms, and in 2002, a Los Angeles court issued an injunction preventing GSK from advertising that the drug was not habit forming. The court withdrew the injunction after the FDA objected that the court had no jurisdiction over drug marketing that the FDA had approved. In 2003, a World Health Organization committee reported that Paxil was among the top 30 drugs, and top three antidepressants, for which dependence had been reported.
Sources: en.wikipedia.org
== Total costs to the US == Obesity has been cited as a contributing factor to approximately 100,000–400,000 deaths in the United States per year (including increased morbidity in car accidents) and has increased health care use and expenditures, costing society an estimated $117 billion in direct (preventive, diagnostic, and treatment services related to weight) and indirect (absenteeism, loss of future earnings due to premature death) costs. This exceeds health-care costs associated with smoking or problem drinking and, by one estimate, accounts for 6% to 12% of national health care expenditures in the United States (although another estimate states the figure is between 5% and 10%). The Medicare and Medicaid programs bear about half of this cost. Annual hospital costs for treating obesity-related diseases in children rose threefold, from US$35 million to US$127 million, in the period from 1979 to 1999, and the inpatient and ambulatory healthcare costs increased drastically by US$395 per person per year. These trends in healthcare costs associated with pediatric obesity and its comorbidities are staggering, urging the Surgeon General to predict that preventable morbidity and mortality associated with obesity may surpass those associated with cigarette smoking. Furthermore, the probability of childhood obesity persisting into adulthood is estimated to increase from approximately twenty percent at four years of age to approximately eighty percent by adolescence, and it is likely that these obesity comorbidities will persist into adulthood.
=== 2020s === 2020: The Nigerian Academy of Science elected epidemiologist/parasitologist Ekanem Braide as its first female president. 2020: Brazilian Scientist and Researcher Jaqueline Goes de Jesus, sequenced COVID-19 genome in 12 hours. 2020: Biochemists Jennifer Doudna (American) and Emmanuelle Charpentier (French) received the Nobel Prize in Chemistry for their work on CRISPR genome editing tool. 2020: American astronomer Andrea M. Ghez received the Nobel Prize in Physics for the discovery of a supermassive compact object. 2020: German-Turkish scientist Özlem Türeci is the co-founder and chief medical officer of BioNTech. Her team developed BNT162b2 (tozinameran (INN)), commonly known as the Pfizer–BioNTech COVID-19 vaccine. 2020: British vaccinologist Sarah Gilbert leads the development and testing of a vaccine which becomes the Oxford–AstraZeneca COVID-19 vaccine. 2021: Catherine Heymans was appointed as the first female Astronomer Royal for Scotland. 2022: American chemist Carolyn R. Bertozzi received the Nobel Prize in Chemistry for her development of Bioorthogonal chemistry. 2023: Australian geomicrobiologist Jillian Banfield became the first female recipient of the van Leeuwenhoek Medal, which she received for her studies of complex microbial communities and their interaction with the environment. 2023: Hungarian American scientist Katalin Kariko receives Noble prize in Physiology or Medicine with Drew Weissman for their discoveries on nucleoside base modifications that enabled the development of effective mRNA vaccines.
=== Sources === Beynon, Erdmann Doane (May 1, 1938). "The Voodoo Cult among Negro migrants in Detroit". American Journal of Sociology. 43 (6): 894–907. doi:10.1086/217872. JSTOR 2768686. S2CID 144039917. Evanzz, Karl (2011) [1999]. The Messenger: The Rise and Fall of Elijah Muhammad (3 ed.). New York City, New York, United States: Knopf Doubleday. ISBN 9780307805201 – via Google Books. Gardell, Mattias (1996). In the Name of Elijah Muhammad: Louis Farrakhan and The Nation of Islam. Durham: Duke University Press. ISBN 978-0822318453.
=== Phase II - conjugation === In subsequent phase II reactions, these activated xenobiotic metabolites are conjugated with charged species such as glutathione (GSH), sulfate, glycine, or glucuronic acid. These reactions are catalysed by a large group of broad-specificity transferases, which in combination can metabolise almost any hydrophobic compound that contains nucleophilic or electrophilic groups. One of the most important of these groups are the glutathione S-transferases (GSTs). The addition of large anionic groups (such as GSH) detoxifies reactive electrophiles and produces more polar metabolites that cannot diffuse across membranes, and may, therefore, be actively transported.
Sources: en.wikipedia.org
The volatility of bromine accentuates its very penetrating, choking, and unpleasant odour. All four stable halogens experience intermolecular van der Waals forces of attraction, and their strength increases together with the number of electrons among all homonuclear diatomic halogen molecules. Thus, the melting and boiling points of bromine are intermediate between those of chlorine and iodine. As a result of the increasing molecular weight of the halogens down the group, the density and heats of fusion and vaporisation of bromine are again intermediate between those of chlorine and iodine, although all their heats of vaporisation are fairly low (leading to high volatility) thanks to their diatomic molecular structure. The halogens darken in colour as the group is descended: fluorine is a very pale yellow gas, chlorine is greenish-yellow, and bromine is a reddish-brown volatile liquid that freezes at −7.2 °C and boils at 58.8 °C. (Iodine is a shiny black solid.) This trend occurs because the wavelengths of visible light absorbed by the halogens increase down the group. Specifically, the colour of a halogen, such as bromine, results from the electron transition between the highest occupied antibonding πg molecular orbital and the lowest vacant antibonding σu molecular orbital. The colour fades at low temperatures so that solid bromine at −195 °C is pale yellow. Liquid bromine is infrared-transparent. Like solid chlorine and iodine, solid bromine crystallises in the orthorhombic crystal system, in a layered arrangement of Br2 molecules.
However, these salts also interact directly with proteins (which are charged and have strong dipole moments) and may even bind specifically (e.g., phosphate and sulfate binding to ribonuclease A). As a result, these interactions can lead to protein denaturation, the formation of artificial adducts, or the partial dissociation of (metal) cofactors, thus, disrupting the delicate balance between apo- and holometalloproteins. Ions that have a strong salting in effect such as I− and SCN− are strong denaturants, because they salt in the peptide group, and thus, interact much more strongly with the unfolded form of a protein than with its native form. Consequently, they shift the chemical equilibrium of the unfolding reaction towards unfolded protein.
Furthermore, given that deficits resulting from mTOR overactivity can be alleviated through treatment with rapamycin, it is possible that mTOR plays an important role in affecting cognitive functioning through synaptic plasticity. Further evidence for mTOR activity in neurodegeneration comes from recent findings demonstrating that eIF2α-P, an upstream target of the mTOR pathway, mediates cell death in prion diseases through sustained translational inhibition. Some evidence points to mTOR's role in reduced Aβ clearance as well. mTOR is a negative regulator of autophagy; therefore, hyperactivity in mTOR signaling should reduce Aβ clearance in the AD brain. Disruptions in autophagy may be a potential source of pathogenesis in protein misfolding diseases, including AD. Studies using mouse models of Huntington's disease demonstrate that treatment with rapamycin facilitates the clearance of huntingtin aggregates. Perhaps the same treatment may be useful in clearing Aβ deposits as well.
as interactive charts on the OECD Data Portal, as interactive databases on iLibrary together with key comparative and country tables, as static files or dynamic database views on the OECD Statistics portal, as StatLinks (in most OECD books, there is a URL that links to the underlying data). In July 2024, the OECD announced that it "has transitioned to [an] open-access information model" and that Creative Commons CC‑BY‑4.0 attribution licences will be used on all data and publications.
== Function == GGT is present in the cell membranes of many tissues, including the kidneys, bile duct, pancreas, gallbladder, spleen, heart, brain, and seminal vesicles. It is involved in the transfer of amino acids across the cellular membrane and leukotriene metabolism. It is also involved in glutathione metabolism by transferring the glutamyl moiety to a variety of acceptor molecules including water, certain L-amino acids, and peptides, leaving the cysteine product to preserve intracellular homeostasis of oxidative stress. This general reaction is:
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.
Cold, dry, and dark conditions are standard, typically at or below minus twenty degrees Celsius for long-term holding. Vials are usually warmed to room temperature before opening to prevent condensation. Repeated warming and cooling of the same vial is generally avoided.
This depends on pH, buffer, and concentration, with acidic conditions often reported as more favorable. Hydrolysis accelerates at room temperature, so solutions are commonly prepared fresh or stored frozen in single-use aliquots. No single shelf life applies across formulations.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.